These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 2663414)

  • 1. Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Gonzalez JP; Henwood JM
    Drugs; 1989 May; 37(5):628-68. PubMed ID: 2663414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Brogden RN
    Drugs; 1985 Feb; 29(2):105-61. PubMed ID: 3884319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Campoli-Richards DM; Monk JP; Price A; Benfield P; Todd PA; Ward A
    Drugs; 1988 Apr; 35(4):373-447. PubMed ID: 3292209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
    Balfour JA; Todd PA; Peters DH
    Drugs; 1995 May; 49(5):794-850. PubMed ID: 7601015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Monk JP; Campoli-Richards DM
    Drugs; 1987 Apr; 33(4):346-91. PubMed ID: 3297617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pefloxacin mesylate--clinical effectiveness in various forms of infectious-inflammatory diseases].
    Pozdniakova VP; Nestetrova LIa; Smirnova LB; Iakovlev VP; Blatun LA; Koshil' OI; Fedorov SM; Bakalova LA; Strachunskiĭ LS; Kurmanova KB
    Antibiot Khimioter; 1997; 42(7):20-3. PubMed ID: 9334143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of pefloxacin activity against recent clinical isolates.
    Lembo M; Covelli B; Nani E; Lavitola A
    J Chemother; 1991 Jan; 3 Suppl 1():51-3. PubMed ID: 12041785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and pharmacokinetic study of pefloxacin in spontaneous ascitic fluid infections].
    Ducroix JP; Hary L; Andrejak M; Smail A; Tondriaux A; Eb F; Baillet J
    Therapie; 1990; 45(6):461-5. PubMed ID: 2080483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral pefloxacin in the treatment of CAPD peritonitis.
    Tan HW; Kon SP; Chua CT; Ngeow NF
    Med J Malaysia; 1992 Jun; 47(2):128-33. PubMed ID: 1494333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pefloxacin in the antibacterial treatment of immunodepressed patients.
    Cajozzo A; Carbone R; Carotenuto M; Grana M; La Sala A; Mancuso S; Perricone R; Sgalambro A; Dammacco F
    J Chemother; 1990 Jun; 2(3):185-9. PubMed ID: 2199629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections.
    Scaglione F; Scamazzo F; Arcidiacono MM; Cogo R; Monzani GP; Fraschini F
    J Chemother; 1995 Apr; 7(2):140-5. PubMed ID: 7666121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections.
    Giamarellou H; Perdikaris G; Galanakis N; Davoulos G; Mandragos K; Sfikakis P
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1362-7. PubMed ID: 2679374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention using pefloxacin of infections in cancer patients with granulocytopenia].
    Leleux A; Snoeck R; Gerain J; Van der Auwera P; Daneau D; Meunier F
    Presse Med; 1989 Jan 7-14; 18(1):21-4. PubMed ID: 2521710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration of pefloxacin in feces during infection prophylaxis in neutropenic patients.
    van de Leur JJ; Vollaard EJ; Janssen AJ; Dofferhoff AS
    Antimicrob Agents Chemother; 1995 May; 39(5):1182-4. PubMed ID: 7625811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.
    Davis R; Bryson HM
    Drugs; 1994 Apr; 47(4):677-700. PubMed ID: 7516863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.
    Peters DH; Clissold SP
    Drugs; 1992 Jul; 44(1):117-64. PubMed ID: 1379907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Bryson HM
    Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.
    Brogden RN; Carmine AA; Heel RC; Speight TM; Avery GS
    Drugs; 1982 Jun; 23(6):405-30. PubMed ID: 7049657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.